750 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Sara Bay Financial

Sara Bay Financial purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 750 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $26,000. Altitude Crest Partners Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth $30,000. V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $52,000. Finally, Prestige Wealth Management Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 69.8% in the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 194 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Evercore ISI upped their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, June 25th. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Finally, UBS Group upped their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,491 shares of company stock worth $15,446,733 in the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Down 0.5 %

Shares of ALNY stock traded down $1.22 on Monday, reaching $266.77. 610,033 shares of the company’s stock were exchanged, compared to its average volume of 871,861. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55. The stock has a market capitalization of $33.74 billion, a PE ratio of -99.54 and a beta of 0.39. The company’s fifty day simple moving average is $267.24 and its 200 day simple moving average is $209.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. Alnylam Pharmaceuticals’s revenue was up 107.0% on a year-over-year basis. During the same period in the prior year, the business posted ($2.21) earnings per share. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.